Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ilexgenin A
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral, Injection
01
Overview
Ilexgenin A is a **pentacyclic triterpenoid** extracted from *Ilex hainanensis Merr.* It is used in research for its **anti-inflammatory** and **anticancer properties**. Ilexgenin A has shown potential in treating various cancers, including human skin cancer, pulmonary carcinoma, and gastric cancer, by inhibiting tumor cell growth in vitro and in vivo[1][2]. It also exhibits anti-inflammatory effects by reducing inflammatory cytokines and modulating signaling pathways[3]. Additionally, it has been studied for its role in improving non-alcoholic fatty liver disease[7].
- Other names
- Ilexgenin A
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)HIF1A (Hypoxia-inducible factor 1-alpha)SREBP-1 / SREBF1 (SREBP-1)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)MAPK3 (Mitogen-activated protein kinase 1)
Beyond the preview
Go deeper on ilexgenin A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ilexgenin A.